Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Logitech Reaffirms Its FY23 Outlook

Outlook Logitech reaffirmed its Fiscal Year 2023 outlook of between negative 8 percent and negative 4 percent sales growth in constant currency, and between $650
byBenzinga Newsdesk
October 25, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Outlook

Logitech reaffirmed its Fiscal Year 2023 outlook of between negative 8 percent and negative 4 percent sales growth in constant currency, and between $650 million and $750 million in non-GAAP operating income.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

GSK Announced Blenrep DREAMM-3 Phase III Did Not Meet Primary Endpoint of Progression-free Survival

By Charles Gross
November 7, 6:05 AM
GSK plc (LSE/NYSE: GSK) today announced that DREAMM-3, the phase III open-label, randomised head-to-head superiority trial of Blenrep (belantamab mafodotin) monotherapy versus pomalidomide in combination with low dose dexamethasone (PomDex) in patients with relapsed or refractory multiple myeloma (RRMM), did not meet its primary endpoint of progression-free survival (PFS).

GSK